Form 4: Vaxcyte SVP Mikhail Eydelman Reports Stock Transactions

Mikhail Eydelman, SVP, General Counsel & Corporate Secretary of Vaxcyte, Inc., reports the acquisition and disposal of company stock and derivative securities.

Summary

• On February 29, 2024, Mikhail Eydelman acquired 10,500 shares of Vaxcyte common stock through restricted stock units (RSUs) at $0.
• On March 1, 2024, Eydelman exercised stock options to acquire 1,667 shares at $21.41 per share.
• Also on March 1, 2024, Eydelman sold 519 shares at a weighted average price of $73.025, 703 shares at a weighted average price of $73.59, and 445 shares at a weighted average price of $74.771.
• On March 2, 2024, 613 shares were surrendered to cover tax withholding obligations at $71.55.
• Following these transactions, Eydelman directly owns 30,597 shares of common stock.
• Eydelman also acquired 50,000 stock options with an exercise price of $73.82 on February 29, 2024.
• After the transactions, Eydelman holds 189,999 stock options with an exercise price of $21.41.

Sentiment

Score: 6

Explanation: The sentiment is neutral. The filing primarily reports routine stock transactions by an executive. The sales are not large enough to indicate significant concern, and the acquisition of RSUs and options is a positive sign.

Positives

• The acquisition of shares through RSUs and stock options demonstrates Eydelman's continued investment in the company.

Negatives

• The sale of shares could be interpreted negatively, although it may be part of a pre-arranged trading plan.

Risks

• Executive stock sales can sometimes signal a lack of confidence, although this is not necessarily the case here.

Industry Context

Form 4 filings are a routine part of the regulatory landscape for publicly traded companies, providing transparency into the transactions of company insiders. These filings are closely watched by investors seeking insights into management's perspective on the company's stock.

Comparison to Industry Standards

• Executive compensation packages often include stock options and RSUs to align management's interests with those of shareholders, which is a common practice among publicly traded companies like Vaxcyte.
• The vesting schedules for the RSUs and stock options are typical, with vesting occurring over several years contingent upon continued service, similar to practices at companies like Moderna and BioNTech.
• The use of 10b5-1 trading plans is a common strategy for corporate insiders to sell shares while avoiding accusations of insider trading, a practice also employed by executives at companies like Pfizer and Johnson & Johnson.

Stakeholder Impact

• The transactions may have a minor impact on shareholders, as insider transactions are often scrutinized for signals about the company's prospects.

Key Dates